SRRA Stock Performance, Insider Transaction and News

SRRA - Sierra Oncology, Inc.

Market Cap	1.34B	P/E	-	EPS this Y	31.70%	Ern Qtrly Grth	-
Income	-94.66M	Forward P/E	-14.25	EPS next Y	26.20%	50D Avg Chg	-
Sales	-	PEG	-0.19	EPS past 5Y	-	200D Avg Chg	63.00%
Dividend	N/A	Price/Book	5.00	EPS next 5Y	59.80%	52W High Chg	-
Recommedations	2.70	Quick Ratio	8.14	Shares Outstanding	24.42M	52W Low Chg	269.00%
Insider Own	8.52%	ROA	-54.52%	Shares Float	9.65M	Beta	0.57
Inst Own	66.68%	ROE	-97.61%	Shares Shorted/Prior	2.29M/1.21M	Price	54.99
Gross Margin	-	Profit Margin	-	Avg. Volume	651,457	Target Price	55.00
Oper. Margin	-	Earnings Date	May 5	Volume		Change	0.00%

Healthcare | Biotechnology | United States

About Sierra Oncology, Inc.

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

SRRA Chatroom

frontiere Posted - 09/28/24

@bs010101 @LASTOCKS19 @thebenchwarmers don’t fall for this loser conspiratorial BS. Whenever a stock doesn’t halt before a major announcement like a trial readout, there’s a whipsaw action as algos and fast manual traders try to react to the news and have opposing views. Plus BEFORE the known catalyst there’s often profit taking / down sizing which can push stock down if supply>demand at that moment. It happens all the time, and is most pronounced in low liquidity high risk sectors like bios. With $SRRA Sierra here in early 2022 pretty sure both of those happened. Feel free to Google the history. 👊

frontiere Posted - 09/27/24

@LASTOCKS19 @thebenchwarmers @bs010101 comparing to $BRNS Barinthus — $SRRA Sierra recapitalized via a $103m PIPE closed on 2019-11-26, w Orbimed + Longitude taking 20% stakes each and old Mgmt ousted. + the a 1:40 reverse split 2020-01-22 (lol because often perception it’s a shitco move… but in fact often is not…). Then after the initial mkt hurrah in early 2020 the share price just started slowly rising (not in a straight line) from $10 to $20+ with volumes similar to those of BRNS … remember being nervous as we wouldn’t be able to get out without a huge vig even during RTH… so we slowly sold off our small pstn at a small profit near $20’s… 🥺 — wild guess but this could be exactly the reason for this persistent offer in BRNS now🧐 https://www.prnewswire.com/news-releases/sierra-oncology-announces-closing-of-103-million-public-offering-and-changes-to-its-board-of-directors-300965034.html

frontiere Posted - 09/27/24

@LASTOCKS19 @thebenchwarmers @bs010101 $BRNS Barinthus 15k shares on the offer while ADV is about the same and actual recent ADV is 1/10 of it 🤔 Why the persistent selling with so little interest… BTW who followed $SRRA Sierra acquired by GSK in 2022 — BRNS remind me the ‘gnashing of teeth’ of longs there, with abysmal volumes between catalysts. We actually bailed for that reason far from the ultimate deal price of $55 per share. 🥺 Will avoid making the same mistake… Or much more recent $NCNA NuCana - have posted on it since spring, and had tiny volumes persistent selling and mostly bearish sentiment here — until the predicted price explosion in Aug and now in Sep… Lastly, quite a few other deep neg EV biotechs with upcoming catalysts have been in that cigar butt abandoned basket though with better volumes — CMRX TIL ACHL CLLS NXTC NKTX BDTX SGTX — yet all of them experienced a turnaround at some point for various reasons and we’ve profited — gotta exercise ACTIVE PAYTIENCE 👍.

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $SRRA Sierra Oncology will be reporting on 11/17/2023 at 7:00AM | Are you anticipating good or poor earnings numbers for this stock?

seforim Posted - 1 year ago

@Watson66 @longrigger52 just look at $SRRA history...

TrendyChart Posted - 10/30/23

Upcoming Earnings Report: $SRRA Sierra Oncology will be reporting on 11/10/2023 at 7:00AM | Are you optimistic or pessimistic about earnings on this stock?

TrendyChart Posted - 1 year ago

Upcoming Earnings Report: $SRRA Sierra Oncology will be reporting on 10/13/2023 at 7:00AM | Are you looking for robust or lackluster earnings from this stock?

seforim Posted - 1 year ago

@PrettyBlob 1) I feel you trust me heres my comment from kpti subreddit: however if you check the 10Ks, you’ll see that RP was granted a ton of options and/or RSUs annually. He has close to 1M shares he was granted when he joined. It makes no sense for him to buy any additional shares on the open market, especially when Executives’ net worth is usually 90% tied up in the biotech company they are in. I doubt his investment advisor thinks he should put additional money to work. Don’t forget that 100% of his time - hopefully - and sweat equity is tied up in the company. His job is to create value, not artificially prop up the stock. Working full time should be the driver for confidence in any company. That being said, he should still buy :) 2) can't buy if in midst of negotiations 3) look at $SRRA a week before buyout announced all of management was selling their pre planned for taxes etc.

DoctorDueDiligence Posted - 1 year ago

@missmadison lol if you only knew Hoping it is bought out like $CTIC / $SRRA as well, but MF is 2025 September.

DoctorDueDiligence Posted - 1 year ago

[Dr. DD] thoughts on $MOR https://twitter.com/DueDoctor/status/1669743893443911681 cc $KPTI $INCY $SRRA $CTIC

Nostradamus696 Posted - 04/25/23

$SGEN $TPTX $SRRA $MYOV. Altimmune smells like a buyout too. I would know 😉

DoctorDueDiligence Posted - 1 year ago

@Watson66 @Pgexchange of course approval isn't required. Many company in this space are acquired due to data (see $SRRA $IMGO). It is curious to me that they canceled the 2nd Line MF which was due to read out this year. Not sure what to make of that. They said capital consideration but as you and I have said - adds to the potential buyout. Hoping that data somehow gets packaged and released even if not full data readout.

midnite_clyde Posted - 1 year ago

$KPTI Keep in mind this is the BEST data in MF, crushing @GSKUS mf drug Momelotinib which they bought for 1.9b from Sierra Oncology $srra

DoctorDueDiligence Posted - 1 year ago

@elmono Also here's my writeup I did last year predicting $SRRA buyout and discussing momelotinib https://www.reddit.com/r/Biotechplays/comments/tq8rse/sierra_oncology_srra_myelofibrosis_disease_state/

risenhoover Posted - 03/26/23

$SRRA SRRA / Sierra Oncology Inc Price Target Updated https://fintel.io/sfo/us/srra?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$SRRA SRRA / Sierra Oncology Inc Price Target Updated https://fintel.io/sfo/us/srra?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/24/23

$SRRA SRRA / Sierra Oncology Inc Price Target Updated https://fintel.io/sfo/us/srra?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/23/23

$SRRA SRRA / Sierra Oncology Inc Price Target Updated https://fintel.io/sfo/us/srra?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/22/23

$SRRA SRRA / Sierra Oncology Inc Price Target Updated https://fintel.io/sfo/us/srra?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget